Format
Sort by
Items per page

Send to

Choose Destination

Best matches for GLATIRAMER/AE:

Search results

Items: 1 to 20 of 37

1.

Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.

Lebrun-Frenay C, Moulignier A, Pierrot-Deseilligny C, Benrabah R, Moreau T, Lubetzki C, Monchecourt F; Copaxone Observatory.

J Neurol. 2019 Apr;266(4):888-901. doi: 10.1007/s00415-019-09211-5. Epub 2019 Feb 7.

2.

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.

Braune S, Grimm S, van Hövell P, Freudensprung U, Pellegrini F, Hyde R, Bergmann A; NTD Study Group.

J Neurol. 2018 Dec;265(12):2980-2992. doi: 10.1007/s00415-018-9083-5. Epub 2018 Oct 16.

3.

Ulnar neuropathy after glatiramer acetate subcutaneous injection: Ultrasound findings.

Coraci D, Giovannini S, Loreti C, Padua L.

J Clin Pharm Ther. 2019 Feb;44(1):140-141. doi: 10.1111/jcpt.12773. Epub 2018 Oct 12. No abstract available.

PMID:
30315577
4.

[Suprapubic Nicolau syndrome following subcutaneous injection of glatiramer acetate].

Blind A, Lenormand C, Schissler C, Cribier B, Lipsker D.

Ann Dermatol Venereol. 2018 Nov;145(11):671-675. doi: 10.1016/j.annder.2018.04.012. Epub 2018 Sep 11. French.

PMID:
30217685
5.

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.

Rommer PS, Zettl UK.

Expert Opin Pharmacother. 2018 Apr;19(5):483-498. doi: 10.1080/14656566.2018.1446944. Epub 2018 Mar 12. Review.

PMID:
29528247
6.

Immunoregulation of Theiler's virus-induced demyelinating disease by glatiramer acetate without suppression of antiviral immune responses.

Omura S, Sato F, Martinez NE, Range T, Ekshyyan L, Minagar A, Alexander JS, Tsunoda I.

Arch Virol. 2018 May;163(5):1279-1284. doi: 10.1007/s00705-018-3729-6. Epub 2018 Jan 23.

7.

[Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].

Boyko AN, Alifirova VM.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(11):135-139. doi: 10.17116/jnevro2017117111135-139. Review. Russian.

PMID:
29265099
8.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

9.

Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk.

Brænne I, Zeng L, Willenborg C, Tragante V, Kessler T; CARDIoGRAM Consortium; CARDIoGRAMplusC4D Consortium, Willer CJ, Laakso M, Wallentin L, Franks PW, Salomaa V, Dehghan A, Meitinger T, Samani NJ, Asselbergs FW, Erdmann J, Schunkert H.

PLoS One. 2017 Aug 22;12(8):e0182999. doi: 10.1371/journal.pone.0182999. eCollection 2017.

10.

[An effect of disease-modifying drugs on the development of children born to mothers with multiple sclerosis].

Kasatkin DS, Spirin NN, Vinogradova TV, Shytova AS.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2. Vyp. 2):85-91. doi: 10.17116/jnevro20171172285-91. Russian.

PMID:
28617366
11.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.

Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. Review.

12.

A Potential Life-Threatening Reaction to Glatiramer Acetate in Rett Syndrome.

Nissenkorn A, Kidon M, Ben-Zeev B.

Pediatr Neurol. 2017 Mar;68:40-43. doi: 10.1016/j.pediatrneurol.2016.11.006. Epub 2016 Dec 7.

PMID:
28254244
13.

Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results.

Selmaj K, Barkhof F, Belova AN, Wolf C, van den Tweel ER, Oberyé JJ, Mulder R, Egging DF, Koper NP, Cohen JA; GATE study group.

Mult Scler. 2017 Dec;23(14):1909-1917. doi: 10.1177/1352458516688956. Epub 2017 Jan 16.

14.

Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.

Bargiela D, Bianchi MT, Westover MB, Chibnik LB, Healy BC, De Jager PL, Xia Z.

Neurology. 2017 Feb 14;88(7):677-684. doi: 10.1212/WNL.0000000000003612. Epub 2017 Jan 13.

15.

Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis.

Ziemssen T, Ashtamker N, Rubinchick S, Knappertz V, Comi G.

Expert Opin Drug Saf. 2017 Feb;16(2):247-255. doi: 10.1080/14740338.2017.1274728. Review.

PMID:
27989217
16.

Management of immediate hypersensitivity reaction to glatiramer acetate.

Amsler E, Autegarden JE, Gaouar H, Frances C, Soria A.

Eur J Dermatol. 2017 Feb 1;27(1):92-95. doi: 10.1684/ejd.2016.2907. No abstract available.

PMID:
27799134
17.

Nicolau syndrome and localized panniculitis: a report of dual diagnoses with an emphasis on morphea profunda-like changes following injection with glatiramer acetate.

Mott SE, Peña ZG, Spain RI, White KP, Ehst BD.

J Cutan Pathol. 2016 Nov;43(11):1056-1061. doi: 10.1111/cup.12791. Epub 2016 Sep 8.

PMID:
27516414
18.

Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.

Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, Kolodny S, Zivadinov R.

Mult Scler. 2017 May;23(6):818-829. doi: 10.1177/1352458516664033. Epub 2016 Aug 8.

PMID:
27503905
19.

Targeting Apoptosis Through Foxp1, and N-cadherin with Glatiramer Acetate in Chick Embryos During Neural Tube Development.

Taskapilioglu MO, Billur D, Kizil S, Taskapilioglu O, Ocakoglu G, Aydin S, Bekar A, Unlu A.

Turk Neurosurg. 2016;26(4):586-94. doi: 10.5137/1019-5149.JTN.14518-15.3.

20.

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.

Kister I, Spelman T, Alroughani R, Lechner-Scott J, Duquette P, Grand'Maison F, Slee M, Lugaresi A, Barnett M, Grammond P, Iuliano G, Hupperts R, Pucci E, Trojano M, Butzkueven H; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1133-7. doi: 10.1136/jnnp-2016-313760. Epub 2016 Jun 13. Erratum in: J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):e2.

PMID:
27298148

Supplemental Content

Loading ...
Support Center